Neurological manifestations of ATTR amyloidosis

被引:0
|
作者
Pernice, Helena F. F. [1 ,2 ]
Hahn, Katrin [1 ,2 ,3 ]
机构
[1] Charite Univ Med Berlin, Amyloidosis Ctr Charite Berlin ACCB, Charitepl 1, D-10117 Berlin, Germany
[2] Charite Univ Med Berlin, Klin Neurol Expt Neurol, Berlin, Germany
[3] Univ Med Berlin, Berlin Inst Hlth Charite BIH, Berlin, Germany
来源
INNERE MEDIZIN | 2023年 / 64卷 / 09期
关键词
Amyloidosis; hereditary; transthyretin-related; Wild-type amyloidosis; Amyloid neuropathies; Tafamidis; RNA interference; HEREDITARY TRANSTHYRETIN AMYLOIDOSIS; LIVER-TRANSPLANTATION; PROGRESSION; TAFAMIDIS; POLYNEUROPATHY; NEUROPATHY; IMPACT;
D O I
10.1007/s00108-023-01570-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Transthyretin amyloidosis (ATTR) is a rare disease in which the protein transthyretin (TTR) is deposited in the form of amyloid fibrils in various tissues and organs and secondarily leads to functional impairment, especially in peripheral nerves and the heart. A differentiation is made between hereditary and sporadic forms. The hereditary variant is inherited in an autosomal dominant manner and usually occurs in the younger to middle-aged, while the sporadic form occurs in older age and has no known genetic cause. Typical signs of hereditary ATTR amyloidosis (ATTRv, v for variant) include a rapidly progressing sensorimotor and autonomic polyneuropathy (PNP), cardiac dysfunction as well as ocular and gastrointestinal symptoms. A carpal tunnel syndrome often precedes the manifestation. Various options (tafamidis, patisiran, inotersen or vutrisiran) are available for the treatment of patients with ATTRv with PNP in Germany, depending on the severity. In the sporadic variant of wild-type ATTR amyloidosis (ATTRwt), symptoms of progressive cardiomyopathy are usually prominent; however, neurological assessment of these patients often also reveals a concomitant sensory ataxic PNP. The tetramer stabilizer tafamidis can be used for treatment. Because of this complex presentation, the management of patients with ATTR amyloidosis should be performed in interdisciplinary centers specialized in amyloidosis.
引用
收藏
页码:848 / 854
页数:7
相关论文
共 50 条
  • [21] Targeted treatments of AL and ATTR amyloidosis
    Chandrashekar, Pranav
    Desai, Anish K.
    Trachtenberg, Barry H.
    HEART FAILURE REVIEWS, 2022, 27 (05) : 1587 - 1603
  • [22] Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis
    Sekijima, Yoshiki
    Tojo, Kana
    Morita, Hiroshi
    Koyama, Jun
    Ikeda, Shu-ichi
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2015, 22 (02): : 79 - 83
  • [23] Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy
    Adams, David
    Ando, Yukio
    Beirao, Joao Melo
    Coelho, Teresa
    Gertz, Morie A.
    Gillmore, Julian D.
    Hawkins, Philip N.
    Lousada, Isabelle
    Suhr, Ole B.
    Merlini, Giampaolo
    JOURNAL OF NEUROLOGY, 2021, 268 (06) : 2109 - 2122
  • [24] Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis
    Lohrmann, Graham
    Pipilas, Alexandra
    Mussinelli, Roberta
    Gopal, Deepa M.
    Berk, John L.
    Connors, Lawreen H.
    Vellanki, Nirupama
    Hellawell, Jennifer
    Siddiqi, Omar K.
    Fox, Jonathan
    Maurer, Mathew S.
    Ruberg, Frederick L.
    JOURNAL OF CARDIAC FAILURE, 2020, 26 (09) : 753 - 759
  • [25] Phenotypic expressions of hereditary Transthyretin Ala97Ser related Amyloidosis (ATTR) in Taiwanese
    Hsu, Hui-Ching
    Liao, Ming-Feng
    Hsu, Jung-Lung
    Lo, Ai-Lun
    Kuo, Hung-Chou
    Lyu, Rong-Kuo
    Wu, Victor Chien-Chia
    Wang, Chih-Wei
    Ro, Long-Sun
    BMC NEUROLOGY, 2017, 17
  • [26] A narrative review and expert recommendations on the assessment of the clinical manifestations, follow-up, and management of post-OLT patients with ATTRv amyloidosis
    Casasnovas, Carlos
    Llado, Laura
    Borrachero, Cristina
    Perez-Santamaria, Patricia Valentina
    Munoz-Beamud, Francisco
    Losada-Lopez, Ines Asuncion
    Baliellas-Comellas, Maria Carme
    Gonzalez-Moreno, Juan
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2023, 16
  • [27] A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis
    Benbrahim, Meissane
    Norman, Kelsey
    Sanchorawala, Vaishali
    Siddiqi, Omar K.
    Hughes, David
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 77 (05) : 544 - 548
  • [28] Systemic ATTR-amyloidosis, a Rare Form of Internal Organ Damage
    Rameev, Vilen V.
    Myasnikov, Roman P.
    Vinogradov, Pavel P.
    Kozlovskaya, Lidiya, V
    Moiseev, Sergei, V
    Fomicheva, Ekaterina, I
    Beregovskaya, Svetlana A.
    Mershina, Elena A.
    Kostina, Svetlana A.
    Strizhakov, Leonid A.
    Rameeva, Anna S.
    Tao, Pavel P.
    Drapkina, Oxana M.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2019, 15 (03) : 349 - 358
  • [29] A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey
    Juan González-Moreno
    Inés Losada-López
    Eugenia Cisneros-Barroso
    Pablo Garcia-Pavia
    José González-Costello
    Francisco Muñoz-Beamud
    Josep Maria Campistol
    Roberto Fernandez-Torron
    Doug Chapman
    Leslie Amass
    Neurology and Therapy, 2021, 10 : 833 - 845
  • [30] Ophthalmological manifestations of hereditary transthyretin amyloidosis
    Gondim, Francisco de Assis Aquino
    Holanda Filha, Joana Gurgel
    Moraes Filho, Manoel Odorico
    ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2022, 85 (05) : 528 - 538